Alpers-Huttenlocher syndrome

Area of Science:

• Mitochondrial genetics
• Neurodegenerative diseases
• Hepatology

Background:

• Alpers-Huttenlocher syndrome (AHS) is a rare mitochondrial disorder.
• It is primarily linked to mutations in the mitochondrial DNA polymerase-gamma (Pol γ).
• Enzyme dysfunction leads to reduced mitochondrial DNA (mtDNA) levels or deletions.

Purpose of the Study:

• To summarize the key features and diagnostic considerations of Alpers-Huttenlocher syndrome.
• To highlight the genetic basis and clinical manifestations of this mitochondrial disease.
• To underscore the progressive and fatal nature of AHS.

Main Methods:

• Review of clinical and genetic literature on Alpers-Huttenlocher syndrome.
• Analysis of phenotypic variability and genotype-phenotype correlations.
• Synthesis of diagnostic criteria based on clinical presentation and genetic findings.

Main Results:

• Mutations in polymerase-gamma disrupt mtDNA maintenance, causing cellular dysfunction.
• Clinical onset varies, with seizures and liver degeneration being common presenting symptoms.
• Disease progression is relentless, leading to liver failure and neurological decline, ultimately proving fatal.

Conclusions:

• Alpers-Huttenlocher syndrome is characterized by progressive neurological and liver failure due to mtDNA defects.
• Diagnosis relies on a constellation of symptoms, as disease presentation is highly variable.
• Despite genetic links, disease tempo and severity show inter-patient variability, impacting prognosis.